Publications by authors named "Michael Karol"

Claim this Profile
I
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.
Henry Hiep Vo, Carrie Cartwright, I-Wen Song, Daniel D Karp, Graciela M Nogueras Gonzalez, Michael Karol

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Xiaoshu Dai, Michael D Karol, Matthew Hitron, Marjie L Hard, Matthew T Goulet

Clin Pharmacol Drug Dev· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass balance and pharmacokinetics of an oral dose of C-napabucasin in healthy adult male subjects.
Xiaoshu Dai, Michael D Karol, Matthew Hitron, Marjie L Hard, John Evan Blanchard

Pharmacol Res Perspect· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
Lipika Goyal, Raymond C Wadlow, Lawrence S Blaszkowsky, Brian M Wolpin, Thomas A Abrams, Michael D Karol

Invest New Drugs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
Jonathan W Goldman, Robert N Raju, Gregory A Gordon, Iman El-Hariry, Florentina Teofilivici, Michael D Karol

BMC Cancer· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Donna E Reece, Dan Sullivan, Sagar Lonial, Ann F Mohrbacher, Gurkamal Chatta, Michael Karol

Cancer Chemother Pharmacol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Karthik Venkatakrishnan, Michael Rader, Ramesh K Ramanathan, Suresh Ramalingam, Eric Chen, Michael Karol

Clin Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
Clarissa E Vergunst, Danielle M Gerlag, Lisa von Moltke, Michael Karol, Tim Wyant

Arthritis Rheum· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Daniel J DeAngelo, Richard M Stone, Mark L Heaney, Stephen D Nimer, Ronald L Paquette, Michael D Karol

Blood· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Fouad Amer, Michael D Karol, Wei-Jian Pan, Janice S Griffin, Nancy L Lukasik

Clin Ther· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
David Gremse, Harland Winter, Vasundhara Tolia, Thirumazhisai Gunasekaran, Wei-Jian Pan, Michael Karol

J Pediatr Gastroenterol Nutr· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
Thirumazhisai Gunasekaran, Sandeep Gupta, David Gremse, Michael Karol, Wei-Jian Pan

J Pediatr Gastroenterol Nutr· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects.
John V. St Peter, Walid M. Awni, G. Richard Granneman, Michael D. Karol

Am J Ther· August 1995

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis